Drug intelligence / Profile preview

lidocaine + bupivacaine + hyaluronidase

Development stage
Phase 1
Lead developer
AstraZeneca
Modality
Therapeutic Enzymes → Recombinant Proteins and Enzymes, Small Molecules
Administration
Peribulbar, Sub-tenon's, Perineural, Infiltration
01

Overview

This is a combination of two amide-type local anesthetics, lidocaine and bupivacaine, with the enzyme hyaluronidase. Lidocaine provides rapid onset of anesthesia, while bupivacaine offers prolonged duration. Hyaluronidase acts as an adjuvant by breaking down hyaluronic acid in connective tissue, increasing tissue permeability and facilitating the spread of local anesthetics. This combination is commonly used for regional anesthesia techniques such as peribulbar or sub-Tenon's blocks in ophthalmic surgery and for peripheral nerve blocks (e.g., brachial plexus block). The addition of hyaluronidase has been shown to hasten the onset and improve the quality of anesthesia by enhancing diffusion through tissues[1][2][3][4]. The mechanism involves sodium channel blockade (lidocaine/bupivacaine) and enzymatic degradation of extracellular matrix components (hyaluronidase).

02

Targets

SCN2A (Voltage-gated sodium channel protein type 2 subunit alpha)SCN3A (Sodium channel protein type 3 subunit alpha)SCN1A (Voltage-gated sodium channel protein type 1 subunit alpha)

Beyond the preview

Go deeper on lidocaine + bupivacaine + hyaluronidase.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on lidocaine + bupivacaine + hyaluronidase.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call